Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.73 |
| ▸ | MAG | P20916 | 6/20 | 0.59 |
| ▸ | SELL | P14151 | 1/20 | 0.55 |
| ▸ | SELP | P16109 | 1/20 | 0.55 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.49 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.49 |
| ▸ | SELE | P16581 | 3/20 | 0.49 |
| ▸ | CD22 | P20273 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12223144 | 1.00 | SIGLEC7 (0.73) | SIGLEC7MAGSELLSELPLGALS8 | |
| SCHEMBL15706045 | 1.00 | SIGLEC7 (0.73) | SIGLEC7MAGSELLSELPLGALS8 | |
| SCHEMBL24368714 | 0.97 | SIGLEC7 (0.74) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL17988587 | 0.92 | SIGLEC7 (0.71) | SIGLEC7MAGSELLSELPLGALS8 | |
| SCHEMBL19248964 | 0.91 | SIGLEC7 (0.74) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL17889798 | 0.90 | SIGLEC7 (0.74) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL17889802 | 0.90 | SIGLEC7 (0.72) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL17897302 | 0.90 | SIGLEC7 (0.72) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL16381196 | 0.90 | SIGLEC7 (0.72) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL17897337 | 0.90 | SIGLEC7 (0.72) | SIGLEC7MAGSELLSELPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221879-B2 | Multiligand constructs | SEMIOTIK LLC (RU) | 2015-12-29 | — | — | US | disclosed |
| US-20140135477-A1 | MULTILIGAND CONSTRUCTS | SEMIOTIK LLC (RU) | 2014-05-15 | — | — | US | disclosed |
| US-8674061-B2 | Multiligand constructs | Smiotik LLC (RU) | 2014-03-18 | — | — | US | disclosed |
| US-20110257081-A1 | MULTIGAND CONSTRUCTS | SEMIOTIK LLC (RU) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257081-A1 | MULTIGAND CONSTRUCTS | KLK3, PAICS, BTD | SIGLEC7 135/4885MAG 148/4885SELL 807/4885 |
| US-20140135477-A1 | MULTILIGAND CONSTRUCTS | KLK3, CD2BP2, PAICS | SIGLEC7 137/4885MAG 214/4885SELL 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.